Interaction Between Rimonabant and Cyclosporine and Tacrolimus
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The major cause of premature death in renal transplant recipients is cardio-vascular disease.
In addition, obesity is becoming a major problem in this patient population. Rimonabant does
not only seem to have weight reducing properties but also weight reduction independent
effects on insulin sensitivity and endothelial function, two important cardio-vascular risk
factors. Rimonabant therefore is an interesting drug for the treatment of transplanted
patients. Present data also indicate that rimonabant does not interact with essential
immunosuppressive drugs (CsA and Tac) indicating that it most probably is safe to administer
to this patient population. However this needs to be investigated in a proper manner.